DK1599455T3 - 4-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansyrederivater og beslægtede forbindelser som PPAR modulatorer til behandling af type 2 diabetes og aterosclerose - Google Patents

4-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansyrederivater og beslægtede forbindelser som PPAR modulatorer til behandling af type 2 diabetes og aterosclerose

Info

Publication number: DK1599455T3
Authority: DK; Denmark
Prior art keywords: ylmethoxy; oxazol; cyclohexyloxy; atherosclerosis; diabetes
Prior art date: 2003-02-27

Application number

DK04712503T

Other languages

English (en)

Inventor

Christian Stapper

Stefanie Keil

Heiner Glombik

Eugen Falk

Jochen Goerlitzer

Dirk Gretzke

Hans-Ludwig Schaefer

Wolfgang Wendler

Original Assignee

Sanofi Aventis Deutschland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-27

Filing date

2004-02-19

Publication date

2009-11-09

2004-02-19 Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland

2009-11-09 Application granted granted Critical

2009-11-09 Publication of DK1599455T3 publication Critical patent/DK1599455T3/da

Links

MSZHFMAFAHIHRC-UHFFFAOYSA-N 4-[3-[(2-phenyl-1,3-oxazol-4-yl)methoxy]cyclohexyl]oxybutanoic acid Chemical class C1C(OCCCC(=O)O)CCCC1OCC1=COC(C=2C=CC=CC=2)=N1 MSZHFMAFAHIHRC-UHFFFAOYSA-N 0.000 title 1
201000001320 Atherosclerosis Diseases 0.000 title 1
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title 1
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
208000001072 type 2 diabetes mellitus Diseases 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)

DK04712503T 2003-02-27 2004-02-19 4-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansyrederivater og beslægtede forbindelser som PPAR modulatorer til behandling af type 2 diabetes og aterosclerose DK1599455T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10308355A DE10308355A1 (de)	2003-02-27	2003-02-27	Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
PCT/EP2004/001586 WO2004076428A1 (de)	2003-02-27	2004-02-19	4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose

Publications (1)

Publication Number	Publication Date
DK1599455T3 true DK1599455T3 (da)	2009-11-09

Family

ID=32920629

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK04712503T DK1599455T3 (da)	2003-02-27	2004-02-19	4-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansyrederivater og beslægtede forbindelser som PPAR modulatorer til behandling af type 2 diabetes og aterosclerose
DK04712494T DK1599453T3 (da)	2003-02-27	2004-02-19	3-Methyl-2-(3-(2-phenyloxazol-4-ylmethyoxy)cyclohexancarbonylamino)smörsyrederivater og beslægtede forbindelser som PPAR modulatorer til behandling af type 2 diabetes og atherosklerose
DK04712490T DK1599452T3 (da)	2003-02-27	2004-02-19	3- (2-phenyloxazol- 4-ylmethoxy) - cyclohexylmethoxyeddikesyrederivater og beslægtede forbindelser som PPAR modulatorer til behandling af type 2 diabetes og atherosklerosw

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DK04712494T DK1599453T3 (da)	2003-02-27	2004-02-19	3-Methyl-2-(3-(2-phenyloxazol-4-ylmethyoxy)cyclohexancarbonylamino)smörsyrederivater og beslægtede forbindelser som PPAR modulatorer til behandling af type 2 diabetes og atherosklerose
DK04712490T DK1599452T3 (da)	2003-02-27	2004-02-19	3- (2-phenyloxazol- 4-ylmethoxy) - cyclohexylmethoxyeddikesyrederivater og beslægtede forbindelser som PPAR modulatorer til behandling af type 2 diabetes og atherosklerosw

Country Status (34)

Country	Link
US (5)	US7259177B2 (da)
EP (3)	EP1599455B1 (da)
JP (3)	JP2006519194A (da)
KR (3)	KR20050105492A (da)
CN (3)	CN100398526C (da)
AR (3)	AR043432A1 (da)
AT (3)	ATE365159T1 (da)
AU (3)	AU2004215673B2 (da)
BR (3)	BRPI0407907A (da)
CA (3)	CA2516620A1 (da)
CL (2)	CL2004000392A1 (da)
CO (2)	CO5690578A2 (da)
DE (4)	DE10308355A1 (da)
DK (3)	DK1599455T3 (da)
EC (2)	ECSP055985A (da)
ES (3)	ES2329366T3 (da)
HR (3)	HRP20050744A2 (da)
IL (2)	IL170316A (da)
MA (3)	MA27737A1 (da)
MX (3)	MXPA05008988A (da)
NO (3)	NO20054408L (da)
OA (2)	OA13034A (da)
PA (1)	PA8596801A1 (da)
PE (3)	PE20040959A1 (da)
PL (3)	PL378130A1 (da)
PT (3)	PT1599452E (da)
RS (1)	RS20050594A (da)
RU (3)	RU2005129995A (da)
SA (1)	SA04250153A (da)
TN (2)	TNSN05206A1 (da)
TW (3)	TW200500349A (da)
UY (2)	UY28210A1 (da)
WO (3)	WO2004076427A1 (da)
ZA (2)	ZA200505768B (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6262118B1 (en) *	1999-06-04	2001-07-17	Metabolex, Inc.	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en)	1999-06-04	2009-08-18	Metabolex, Inc.	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US7399777B2 (en) *	2001-08-31	2008-07-15	Sanofi-Aventis Deutschland Gmbh	Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) *	2003-02-27	2004-12-02	Aventis Pharma Deutschland Gmbh	Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) *	2004-08-07	2006-08-31	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039533B4 (de)	2004-08-14	2006-09-28	Sanofi-Aventis Deutschland Gmbh	Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039532B4 (de) *	2004-08-14	2006-09-21	Sanofi-Aventis Deutschland Gmbh	Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de)	2004-08-14	2006-09-21	Sanofi-Aventis Deutschland Gmbh	Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004060227B3 (de)	2004-12-15	2006-07-20	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) *	2005-06-10	2007-03-28		Formulación y proceso de compresión directa
CA2624102A1 (en)	2005-09-29	2007-04-12	Sanofi-Aventis	Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
BRPI0621960A2 (pt)	2006-08-10	2011-12-27	Wood One Co Ltd	composiÇço hipoglicÊmica contendo derivado da casca de acÁcia
EP2181087B1 (en)	2007-08-16	2015-10-14	Solvay Sa	Process for the preparation of esters of 4-fluorosubstituted 3-oxo-alcanoic acids
CN103435593B (zh) *	2008-02-29	2015-01-28	日产化学工业株式会社	噻吩化合物及其中间体的制造方法
US7615661B2 (en) *	2008-03-12	2009-11-10	International Flavors & Fragrances Inc.	Thioester compounds and their use in fragrance or flavor applications
KR102640007B1 (ko)	2017-12-13	2024-02-27	캐논 가부시끼가이샤	프로세스 카트리지
CN109810071B (zh) *	2019-03-28	2023-04-21	中国科学院成都生物研究所	一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2663336B1 (fr)	1990-06-18	1992-09-04	Adir	Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) *	1990-06-19	1992-09-11	Commissariat Energie Atomique	Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
IL108634A0 (en)	1993-02-15	1994-05-30	Wellcome Found	Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
IL108633A (en)	1993-02-15	1998-07-15	Wellcome Found	History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
JP3144624B2 (ja)	1995-06-02	2001-03-12	杏林製薬株式会社	Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
CZ220498A3 (cs)	1996-01-17	1998-11-11	Novo Nordisk A/S	Deriváty 1,2,4-thiadiazinu a 1,4-thiazinu, příprava a použití
JP3149958B2 (ja)	1996-08-30	2001-03-26	ノボノルディスクアクティーゼルスカブ	Ｇｌｐ―１誘導体
TW492957B (en)	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
DE69723869T2 (de)	1996-12-31	2004-04-22	Dr. Reddy's Laboratories Ltd.	Heterozyklische verbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen die diese enthalten und ihre anwendung in der behandlung von diabetis und verwandten krankheiten
DE19726167B4 (de) *	1997-06-20	2008-01-24	Sanofi-Aventis Deutschland Gmbh	Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
EP1000066A1 (en)	1997-07-16	2000-05-17	Novo Nordisk A/S	Fused 1,2,4-thiadiazine derivatives, their preparation and use
CO4970713A1 (es)	1997-09-19	2000-11-07	Sanofi Synthelabo	Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
JP4345230B2 (ja) *	1998-03-10	2009-10-14	小野薬品工業株式会社	カルボン酸誘導体およびその誘導体を有効成分として含有する薬剤
DE19823831A1 (de)	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
MA26634A1 (fr)	1998-06-04	2004-12-20	Astra Ab	Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv)	1998-06-04	1998-06-04	Astra Ab	New 3-aryl-2-hydroxypropionic acid derivative I
US6221897B1 (en) *	1998-06-10	2001-04-24	Aventis Pharma Deutschland Gmbh	Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828114A1 (de)	1998-06-24	2000-01-27	Probiodrug Ges Fuer Arzneim	Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de)	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
AU5443499A (en) *	1998-08-27	2000-03-21	Ono Pharmaceutical Co. Ltd.	Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19845405C2 (de) *	1998-10-02	2000-07-13	Aventis Pharma Gmbh	Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en)	1999-01-08	1999-02-24	Alizyme Therapeutics Ltd	Inhibitors
DE19916108C1 (de) *	1999-04-09	2001-01-11	Aventis Pharma Gmbh	Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
WO2000063208A1 (en)	1999-04-16	2000-10-26	Novo Nordisk A/S	Substituted imidazoles, their preparation and use
US6908926B1 (en) *	1999-04-16	2005-06-21	Novo Nordisk A/S	Substituted imidazoles, their preparation and use
IL145922A0 (en)	1999-04-28	2002-07-25	Aventis Pharma Gmbh	Di-aryl acid derivatives as ppar receptor ligands
PT1177176E (pt) *	1999-04-28	2006-08-31	Aventis Pharma Gmbh	Derivados de acidos triarilicos como ligandos de receptores ppar.
CA2371271A1 (en)	1999-04-30	2000-11-09	Neurogen Corporation	9h-pyrimido[4,5-b]indole derivatives: crf1 specific ligands
GB9911863D0 (en)	1999-05-21	1999-07-21	Knoll Ag	Therapeutic agents
CA2376919C (en)	1999-06-18	2008-11-04	Merck & Co., Inc.	Arylthiazolidinedione and aryloxazolidinedione derivatives
US6413737B1 (en)	1999-07-09	2002-07-02	Cohesion Technologies, Inc.	Ecarin prothrombin protease and methods
DK1204654T3 (da)	1999-07-29	2003-11-17	Lilly Co Eli	Benzofurylpiperaziner og benzofurylhomopiperaziner: Serotonin agonister
BR0013727A (pt) *	1999-09-01	2002-05-07	Aventis Pharma Gmbh	Derivados de sulfonilcarboxamida, processo para sua preparação e seu uso como medicamento
TW200528436A (en)	1999-09-22	2005-09-01	Bristol Myers Squibb Co	Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
ES2215769T3 (es)	1999-12-03	2004-10-16	Astrazeneca Ab	Forma cristalina de acido (s)-2-etoxi-3-(4-(2-(4-metanosulfoniloxifenil)etoxi)fenil)propanoico.
SE9904413D0 (sv)	1999-12-03	1999-12-03	Astra Ab	Comminuted form
AU2001254763A1 (en)	2000-03-31	2001-10-08	Prosidion Limited	Method for the improvement of islet signaling in diabetes mellitus and for its prevention
HUP0300475A3 (en)	2000-04-25	2004-10-28	Kyorin Seiyaku Kk	Novel stable crystal of thiazolidinedione derivative and process for producing the same
PT1277736E (pt)	2000-04-28	2007-10-12	Asahi Kasei Pharma Corp	Novos compostos bicíclicos
JP2004507456A (ja)	2000-05-11	2004-03-11	ブリストル−マイヤーズ　スクイブ　カンパニー	成長ホルモン分泌促進薬として有用なテトラヒドロイソキノリン類縁体
AU2001264977B2 (en)	2000-05-30	2005-04-14	Merck & Co., Inc.	Melanocortin receptor agonists
EP1294682B1 (de) *	2000-06-09	2004-04-28	Aventis Pharma Deutschland GmbH	Acylphenylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE10038709A1 (de)	2000-08-09	2002-02-28	Aventis Pharma Gmbh	Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) *	2000-08-11	2002-02-27	Yissum Research Development Company of the Hebrew University of Jerusalem	Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
DE60129712T2 (de)	2000-08-23	2008-07-03	Eli Lilly And Co., Indianapolis	Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
CA2418104A1 (en) *	2000-08-23	2002-02-28	Eli Lilly And Company	Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
TWI243162B (en)	2000-11-10	2005-11-11	Taisho Pharmaceutical Co Ltd	Cyanopyrrolidine derivatives
AU2002222573A1 (en)	2000-12-05	2002-06-18	Kyorin Pharmaceutical Co. Ltd.	Substituted carboxylic acid derivatives
GB0031103D0 (en) *	2000-12-20	2001-01-31	Glaxo Group Ltd	Chemical compounds
HUP0401081A3 (en)	2000-12-21	2010-06-28	Sanofi Aventis Deutschland	Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and their use
NZ526687A (en) *	2000-12-25	2004-08-27	Ono Pharmaceutical Co	Dihydronaphthalene derivative compounds and drugs containing these compounds as the active ingredient
EP1360172A1 (en) *	2001-02-15	2003-11-12	Pfizer Products Inc.	Ppar agonists
PE20021091A1 (es)	2001-05-25	2003-02-04	Aventis Pharma Gmbh	Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
EA200400011A1 (ru) *	2001-06-07	2004-06-24	Эли Лилли Энд Компани	Модуляторы рецепторов, активируемых пролифераторами пероксисом (prar)
DE10154689A1 (de)	2001-11-09	2003-05-22	Probiodrug Ag	Substituierte Aminoketonverbindungen
WO2003004458A1 (en)	2001-07-03	2003-01-16	Biovitrum Ab	New compounds
FR2827859B1 (fr)	2001-07-30	2005-09-23	Lipha	Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
JP4436129B2 (ja)	2001-08-31	2010-03-24	サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	ジアリールシクロアルキル誘導体、その製造法及びｐｐａｒ−活性剤としてのその使用
WO2003066581A1 (en)	2002-02-05	2003-08-14	Eli Lilly And Company	Urea linker derivatives for use as ppar modulators
DE10215908B4 (de)	2002-04-11	2005-08-18	Aventis Pharma Deutschland Gmbh	Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10215907A1 (de)	2002-04-11	2003-11-06	Aventis Pharma Gmbh	Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10225635C1 (de)	2002-06-07	2003-12-24	Aventis Pharma Gmbh	N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
AU2003259131A1 (en)	2002-07-09	2004-01-23	Bristol-Myers Squibb Company	Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7148246B2 (en) *	2003-02-27	2006-12-12	Sanofi-Aventis Deutschland Gmbh	Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

2003
- 2003-02-27 DE DE10308355A patent/DE10308355A1/de not_active Withdrawn
2004
- 2004-02-19 PT PT04712490T patent/PT1599452E/pt unknown
- 2004-02-19 DE DE502004009690T patent/DE502004009690D1/de not_active Expired - Lifetime
- 2004-02-19 AU AU2004215673A patent/AU2004215673B2/en not_active Ceased
- 2004-02-19 AT AT04712490T patent/ATE365159T1/de not_active IP Right Cessation
- 2004-02-19 DK DK04712503T patent/DK1599455T3/da active
- 2004-02-19 DK DK04712494T patent/DK1599453T3/da active
- 2004-02-19 MX MXPA05008988A patent/MXPA05008988A/es active IP Right Grant
- 2004-02-19 DK DK04712490T patent/DK1599452T3/da active
- 2004-02-19 EP EP04712503A patent/EP1599455B1/de not_active Expired - Lifetime
- 2004-02-19 OA OA1200500247A patent/OA13034A/en unknown
- 2004-02-19 OA OA1200500248A patent/OA13035A/en unknown
- 2004-02-19 AU AU2004215672A patent/AU2004215672B2/en not_active Ceased
- 2004-02-19 PT PT04712494T patent/PT1599453E/pt unknown
- 2004-02-19 RU RU2005129995/04A patent/RU2005129995A/ru not_active Application Discontinuation
- 2004-02-19 JP JP2006501886A patent/JP2006519194A/ja active Pending
- 2004-02-19 DE DE502004004139T patent/DE502004004139D1/de not_active Expired - Lifetime
- 2004-02-19 CA CA002516620A patent/CA2516620A1/en not_active Abandoned
- 2004-02-19 PL PL378130A patent/PL378130A1/pl not_active Application Discontinuation
- 2004-02-19 CN CNB2004800054985A patent/CN100398526C/zh not_active Expired - Fee Related
- 2004-02-19 AU AU2004215677A patent/AU2004215677B2/en not_active Ceased
- 2004-02-19 ES ES04712503T patent/ES2329366T3/es not_active Expired - Lifetime
- 2004-02-19 CA CA002517386A patent/CA2517386A1/en not_active Abandoned
- 2004-02-19 PT PT04712503T patent/PT1599455E/pt unknown
- 2004-02-19 BR BRPI0407907-8A patent/BRPI0407907A/pt not_active IP Right Cessation
- 2004-02-19 AT AT04712503T patent/ATE435217T1/de not_active IP Right Cessation
- 2004-02-19 RU RU2005130002/04A patent/RU2005130002A/ru not_active Application Discontinuation
- 2004-02-19 AT AT04712494T patent/ATE430738T1/de not_active IP Right Cessation
- 2004-02-19 HR HR20050744A patent/HRP20050744A2/xx not_active Application Discontinuation
- 2004-02-19 BR BRPI0407758-0A patent/BRPI0407758A/pt not_active IP Right Cessation
- 2004-02-19 PL PL377735A patent/PL377735A1/pl not_active Application Discontinuation
- 2004-02-19 JP JP2006501892A patent/JP2006519199A/ja active Pending
- 2004-02-19 KR KR1020057015851A patent/KR20050105492A/ko not_active Ceased
- 2004-02-19 JP JP2006501885A patent/JP2006519193A/ja active Pending
- 2004-02-19 WO PCT/EP2004/001579 patent/WO2004076427A1/de not_active Ceased
- 2004-02-19 WO PCT/EP2004/001586 patent/WO2004076428A1/de not_active Ceased
- 2004-02-19 CN CNB2004800054379A patent/CN100439345C/zh not_active Expired - Fee Related
- 2004-02-19 HR HR20050743A patent/HRP20050743A2/xx not_active Application Discontinuation
- 2004-02-19 HR HR20050742A patent/HRP20050742A2/xx not_active Application Discontinuation
- 2004-02-19 RS YUP-2005/0594A patent/RS20050594A/sr unknown
- 2004-02-19 CA CA002517381A patent/CA2517381A1/en not_active Abandoned
- 2004-02-19 KR KR1020057015995A patent/KR20050106461A/ko not_active Ceased
- 2004-02-19 MX MXPA05008951A patent/MXPA05008951A/es active IP Right Grant
- 2004-02-19 WO PCT/EP2004/001578 patent/WO2004076426A1/de not_active Ceased
- 2004-02-19 ES ES04712490T patent/ES2287700T3/es not_active Expired - Lifetime
- 2004-02-19 MX MXPA05008995A patent/MXPA05008995A/es active IP Right Grant
- 2004-02-19 EP EP04712490A patent/EP1599452B1/de not_active Expired - Lifetime
- 2004-02-19 EP EP04712494A patent/EP1599453B1/de not_active Expired - Lifetime
- 2004-02-19 PL PL378437A patent/PL378437A1/pl not_active Application Discontinuation
- 2004-02-19 KR KR1020057016023A patent/KR20050106462A/ko not_active Ceased
- 2004-02-19 CN CNB2004800054769A patent/CN100439347C/zh not_active Expired - Fee Related
- 2004-02-19 BR BRPI0407814-4A patent/BRPI0407814A/pt not_active IP Right Cessation
- 2004-02-19 ES ES04712494T patent/ES2326418T3/es not_active Expired - Lifetime
- 2004-02-19 DE DE502004009453T patent/DE502004009453D1/de not_active Expired - Lifetime
- 2004-02-19 RU RU2005129992/04A patent/RU2005129992A/ru not_active Application Discontinuation
- 2004-02-25 TW TW093104704A patent/TW200500349A/zh unknown
- 2004-02-25 TW TW093104705A patent/TW200510352A/zh unknown
- 2004-02-25 TW TW093104697A patent/TW200508210A/zh unknown
- 2004-02-27 US US10/788,996 patent/US7259177B2/en not_active Expired - Lifetime
- 2004-02-27 PE PE2004000206A patent/PE20040959A1/es not_active Application Discontinuation
- 2004-02-27 UY UY28210A patent/UY28210A1/es unknown
- 2004-02-27 AR ARP040100635A patent/AR043432A1/es not_active Application Discontinuation
- 2004-02-27 CL CL200400392A patent/CL2004000392A1/es unknown
- 2004-02-27 AR ARP040100629A patent/AR043427A1/es not_active Application Discontinuation
- 2004-02-27 PE PE2004000203A patent/PE20050292A1/es not_active Application Discontinuation
- 2004-02-27 US US10/788,997 patent/US7365084B2/en not_active Expired - Fee Related
- 2004-02-27 PA PA20048596801A patent/PA8596801A1/es unknown
- 2004-02-27 AR ARP040100636A patent/AR043433A1/es not_active Application Discontinuation
- 2004-02-27 UY UY28209A patent/UY28209A1/es unknown
- 2004-02-27 PE PE2004000205A patent/PE20050293A1/es not_active Application Discontinuation
- 2004-02-27 CL CL200400391A patent/CL2004000391A1/es unknown
- 2004-02-27 US US10/789,017 patent/US7335671B2/en not_active Expired - Lifetime
- 2004-06-09 SA SA04250153A patent/SA04250153A/ar unknown
2005
- 2005-07-19 ZA ZA200505768A patent/ZA200505768B/en unknown
- 2005-07-19 ZA ZA200505765A patent/ZA200505765B/en unknown
- 2005-08-16 IL IL170316A patent/IL170316A/en not_active IP Right Cessation
- 2005-08-16 IL IL170314A patent/IL170314A/en not_active IP Right Cessation
- 2005-08-26 MA MA28460A patent/MA27737A1/fr unknown
- 2005-08-26 MA MA28459A patent/MA27736A1/fr unknown
- 2005-08-26 EC EC2005005985A patent/ECSP055985A/es unknown
- 2005-08-26 CO CO05085499A patent/CO5690578A2/es not_active Application Discontinuation
- 2005-08-26 CO CO05085508A patent/CO5690580A2/es not_active Application Discontinuation
- 2005-08-26 TN TNP2005000206A patent/TNSN05206A1/en unknown
- 2005-08-26 MA MA28465A patent/MA27742A1/fr unknown
- 2005-08-26 TN TNP2005000204A patent/TNSN05204A1/en unknown
- 2005-08-26 EC EC2005005986A patent/ECSP055986A/es unknown
- 2005-09-22 NO NO20054408A patent/NO20054408L/no unknown
- 2005-09-22 NO NO20054396A patent/NO20054396L/no unknown
- 2005-09-22 NO NO20054398A patent/NO20054398L/no unknown
2007
- 2007-08-16 US US11/839,950 patent/US20080015238A1/en not_active Abandoned
2008
- 2008-01-14 US US12/013,806 patent/US7872034B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2516620A1 (en)	2004-09-10
ATE435217T1 (de)	2009-07-15
AR043427A1 (es)	2005-07-27
CO5690580A2 (es)	2006-10-31
AU2004215672A1 (en)	2004-09-10
WO2004076426A1 (de)	2004-09-10
NO20054408D0 (no)	2005-09-22
OA13034A (en)	2006-11-10
EP1599453A1 (de)	2005-11-30
JP2006519194A (ja)	2006-08-24
MXPA05008951A (es)	2005-11-04
PL378130A1 (pl)	2006-03-06
ATE430738T1 (de)	2009-05-15
CA2517381A1 (en)	2004-09-10
DE10308355A1 (de)	2004-12-23
DK1599452T3 (da)	2007-10-01
MXPA05008988A (es)	2005-10-18
OA13035A (en)	2006-11-10
MA27736A1 (fr)	2006-02-01
HRP20050742A2 (en)	2006-09-30
NO20054398L (no)	2005-11-02
NO20054396D0 (no)	2005-09-22
RU2005129995A (ru)	2006-01-27
SA04250153A (ar)	2005-12-03
US7259177B2 (en)	2007-08-21
TNSN05206A1 (en)	2007-06-11
AU2004215673B2 (en)	2009-10-01
US20050215596A1 (en)	2005-09-29
ECSP055986A (es)	2006-01-16
NO20054408L (no)	2005-11-23
PA8596801A1 (es)	2004-09-16
RS20050594A (sr)	2007-12-31
HRP20050744A2 (en)	2006-09-30
AU2004215677A1 (en)	2004-09-10
US20040209920A1 (en)	2004-10-21
ZA200505768B (en)	2005-11-23
HRP20050743A2 (en)	2006-08-31
IL170316A (en)	2010-11-30
MA27742A1 (fr)	2006-02-01
US7365084B2 (en)	2008-04-29
CN1753881A (zh)	2006-03-29
KR20050106461A (ko)	2005-11-09
CN100439347C (zh)	2008-12-03
NO20054396L (no)	2005-11-11
AU2004215673A1 (en)	2004-09-10
ATE365159T1 (de)	2007-07-15
BRPI0407907A (pt)	2006-02-14
PT1599452E (pt)	2007-09-12
PE20050293A1 (es)	2005-05-24
AU2004215677B2 (en)	2010-01-07
US20080015238A1 (en)	2008-01-17
PT1599455E (pt)	2009-09-29
BRPI0407814A (pt)	2006-02-14
RU2005130002A (ru)	2006-01-27
US7335671B2 (en)	2008-02-26
PT1599453E (pt)	2009-07-14
KR20050105492A (ko)	2005-11-04
MA27737A1 (fr)	2006-02-01
IL170314A (en)	2010-11-30
MXPA05008995A (es)	2005-10-18
AU2004215672B2 (en)	2010-01-07
KR20050106462A (ko)	2005-11-09
TNSN05204A1 (en)	2007-06-11
US20050101637A1 (en)	2005-05-12
WO2004076428A1 (de)	2004-09-10
NO20054398D0 (no)	2005-09-22
CN1756748A (zh)	2006-04-05
PL378437A1 (pl)	2006-04-03
EP1599455B1 (de)	2009-07-01
EP1599452A1 (de)	2005-11-30
WO2004076427A1 (de)	2004-09-10
US20080167354A1 (en)	2008-07-10
CO5690578A2 (es)	2006-10-31
DK1599453T3 (da)	2009-08-24
AR043432A1 (es)	2005-07-27
CL2004000392A1 (es)	2005-04-22
UY28210A1 (es)	2004-09-30
PE20040959A1 (es)	2005-01-17
EP1599455A1 (de)	2005-11-30
TW200508210A (en)	2005-03-01
EP1599453B1 (de)	2009-05-06
DE502004004139D1 (de)	2007-08-02
US7872034B2 (en)	2011-01-18
CN100398526C (zh)	2008-07-02
PL377735A1 (pl)	2006-02-20
UY28209A1 (es)	2004-09-30
TW200500349A (en)	2005-01-01
CL2004000391A1 (es)	2005-01-07
CA2517386A1 (en)	2004-09-10
ES2287700T3 (es)	2007-12-16
CN1753879A (zh)	2006-03-29
EP1599452B1 (de)	2007-06-20
RU2005129992A (ru)	2006-02-10
JP2006519199A (ja)	2006-08-24
ES2329366T3 (es)	2009-11-25
ECSP055985A (es)	2006-01-16
AR043433A1 (es)	2005-07-27
ZA200505765B (en)	2006-05-31
DE502004009453D1 (de)	2009-06-18
TW200510352A (en)	2005-03-16
JP2006519193A (ja)	2006-08-24
PE20050292A1 (es)	2005-05-24
CN100439345C (zh)	2008-12-03
BRPI0407758A (pt)	2006-02-14
ES2326418T3 (es)	2009-10-09
DE502004009690D1 (de)	2009-08-13

Publication	Publication Date	Title
NO20054398D0 (no)	2005-09-22	4-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksyloksy)-butansyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose
DK1651621T3 (da)	2008-11-10	2-(Quinoxalin-5-ylsulfonylamino)benzamidforbindelser som CCK2-modulatorer
DK1423381T3 (da)	2007-05-07	17beta-hydroxysteroid-dehydrogenase type 3-inhibitorer til behandling af androgenafhængige sygdomme
DK2173730T3 (da)	2014-01-20	Hidtil ukendte forbindelser 951: biphenyloxypropansyre som crth2-modulator og mellemprodukter
DK1732562T3 (da)	2008-04-28	Substituerede pyridinyl- og pyrimidinylderivater som modulatorer af metabolisme og behandling af forstyrrelser relateret dertil
NO20061420L (no)	2006-03-28	3-[(2-{4-Heksyloksykarbonylamino-Imino-metyl)-Fenylamino]-Metyl}-1-Metyl-1H-Benzimidazol-5-Karbonyl)-Pyridin-2-yl-Amino]-Propansyre Etylester Metansulfonat og
DK1488790T3 (da)	2014-10-13	Fast præparat indeholdende en enkeltkrystalform A af etthiazolcarboxylsyrederivat
PL2937341T3 (pl)	2017-11-30	Pochodne fenyloamidowe kwasu 4-(benzylo)-piperazyno-1-karboksylowego oraz związki powiązane, jako modulatory hydrolazy amidu kwasu tłuszczowego (FAAH) do leczenia lęku, bólu i innych schorzeń
UA104987C2 (uk)	2014-04-10	Похідні 3-(2,6-диметилбензилокси)фенілоцтової кислоти
NO20055370D0 (no)	2005-11-14	Alfa-substituert karboksylsyre som PPAR modulatorer
DK1432701T3 (da)	2006-05-08	Heterocycliske forbindelser til anvendelse ved behandlingen af lidelser i urinvejene
DK1968949T3 (da)	2011-01-24	Forbedret fremgangsmåde til fremstilling af salte af 4-(benzimidazolylmethylamino)-benzamider
DK1206436T3 (da)	2005-02-14	Retinoider til behandling af emfysem
NO20045554L (no)	2004-12-20	Fremgangsmate for behandling av diabetes
DK1539746T3 (da)	2007-03-26	N-substituerede 1H-indol-5-propionsyre-forbindelser som PPAR-agonister der er nyttige til behandling af diabetes
DK1519928T3 (da)	2014-08-04	Fremgangsmåde til fremstilling af heterocykliske fluoralkenylsulfoner
DK1828151T3 (da)	2011-05-16	Malonamidderivater som inhibitorer af gamma-sekretase til behandlingen af alzheimer's sygdom
DK1789403T3 (da)	2009-07-06	N-(phenyl-oxazol-4ylmethoxymethyl)-cyclohexyl-ravsyreamid derivater og beslægtede forbindelser som PPAR-ligander (peroxisom-proliferator-aktiverede receptorer) til behandling af hyperlipidæmi og diabetes
DK1197485T3 (da)	2004-11-29	Cyclobutendionderivater til behandling af artherosclerose
DE602004015207D1 (de)	2008-09-04	Offline markierungslose Nachverarbeitung von Aufzeichnungsmaterialien
DK1963307T3 (da)	2010-04-06	3-(4-{[4-(4-{[3-(3,3-dimethyl-1-piperidinyl)propyl]oxy}phenyl)-1-piperidinyl]carbonyl}-1-naphthalenyl)propion- eller propensyre som H1- og H3-receptorantagonister til behandling af inflammatoriske og/eller allergiske lidelser
NO20050885D0 (no)	2005-02-18	Ny fremgangsmate for syntesen av 1,3-dihydro-2H-3-benzazepin-2-onforbindelser, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre
ATE366576T1 (de)	2007-08-15	Neue kristallmodifikation von 2-(3,5-bis- trifluormethyl-phenyl)-n-6-(1,1-dioxo-1lamda-6-
DK1497290T3 (da)	2008-12-15	Fremgangsmåde til fremstilling af syresalte af gemifloxacin
DE60311284D1 (de)	2007-03-08	4-(3,5-dicyanophenoxy)pyrazol-derivate zur verwendung als reverse transkriptase modulatoren zur behandlung von u.a. hiv